Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...

The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as Lynk Pharmaceuticals), a clinical stage innovative drug ...

A veteran FDA regulator who left last month said the firewall between agency political appointees and drug reviewers “has ...

A Dingwall rheumatoid arthritis sufferer was waiting to be medically prescribed cannabis for pain relief but continued to ...

Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.

The clinical trial is expected to enroll up to 40 patients in two stages: an initial open-label pilot (10 patients) followed by a randomized, double-blinded, sham-controlled trial (30 patients).

AbbVie on Wednesday denied it was in talks to buy Revolution Medicines after the Wall Street Journal reported the drugmaker ...

The NHS has issued an important message to people taking a common medication for osteoarthritis. According to Arthritis UK, ...